Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,496 across all filing types
Latest filing 2026-05-27 Proxy Solicitation & In…
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
关于召开2026年第一次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 91% confidence The document is a formal notice convening the 2026 First Extraordinary General Meeting of shareholders, detailing the meeting date, location, agenda proposals, voting methods, proxy authorization form, and registration procedures. It serves as proxy solicitation materials to inform and guide shareholders on how to vote and appoint proxies. This fits the definition of a Proxy Solicitation & Information Statement (PSI) rather than the meeting results, an annual report, or another form.
2026-05-27 Chinese
关于拟注册发行银行间债券市场非金融企业债务融资工具的公告
Capital/Financing Update Classification · 90% confidence The document is an announcement by Yifan Pharma Co., Ltd. regarding the proposed registration and issuance of non-financial enterprise debt financing instruments in the interbank bond market, detailing issuance size, instruments, purposes, board and shareholder authorization, approval procedures, and risk warnings. This is a financing update related to bond issuance, fitting the Capital/Financing Update category rather than a full report or regulatory filing.
2026-05-27 Chinese
关于回购公司股份并用于注销的公告
Transaction in Own Shares Classification · 97% confidence The document is a formal announcement by a listed company detailing a share buyback program: purpose, price range, quantity, funding source, implementation period, and cancellation of repurchased shares. This fits the definition of a Transaction in Own Shares (share repurchase) rather than a financial report or dividend notice.
2026-05-27 Chinese
2025年年度分红派息实施公告
Notice of Dividend Amount Classification · 91% confidence The document is an official announcement detailing the company’s 2025 annual dividend distribution plan, specifying the dividend amount per share, record date, ex-dividend date, payment method, and related procedures. This matches the definition of a Notice of Dividend Amount (DIV).
2026-05-21 Chinese
安徽天禾律师事务所关于亿帆医药股份有限公司2025年年度股东会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 80% confidence The document is a legal opinion letter from a law firm covering the company’s 2025 Annual General Meeting, with exhaustive tables of vote counts and approval percentages for each resolution. It provides the formal, official voting results of the AGM (e.g. votes for the 2025 board report, annual report, profit distribution proposal, auditor reappointment, remuneration resolution, etc.). This matches the “Declaration of Voting Results & Voting Rights Announcements” category, which covers official vote results from shareholder meetings.
2026-05-18 Chinese
关于全资子公司收到药品注册受理通知书的公告
Regulatory Filings Classification · 82% confidence The document is a formal public announcement by a listed company regarding its subsidiary receiving a drug registration acceptance notice from the national drug regulator. It does not contain financial statements, executive certifications, or meeting materials, nor is it an earnings release, share transaction, or governance filing. This fits the general regulatory announcement category (fallback).
2026-05-15 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.